Cyteir Therapeutics, Inc. Profile Avatar - Palmy Investing

Cyteir Therapeutics, Inc.

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II …

Biotechnology
US, Lexington [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Cyteir Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of CYT's Analysis
CIK: 1662244 CUSIP: - ISIN: US23284P1030 LEI: - UEI: -
Secondary Listings
CYT has no secondary listings inside our databases.